Sign up
Pharma Capital

Nanobiotix highlights more encouraging immunotherapy data from its cancer treatment

This ability to turn tumours ‘hot’ is seen as key to help a person’s immune system fight their cancer.
picture of cell
Nanobiotix's lead treatment is showing promising immunotherapy indications

Cancer treatment pioneer Nanobiotix SA (EPN:NANO) has presented new data illustrating how its lead treatment, NBTXR3, can help the body’s immune system fight tumours.

In a presentation to an Immunotherapy workshop co-sponsored by the American Society of Radiation Oncology (ASTRO), the National Cancer Institute (NCI) and the Society for Immunotherapy of Cancer (SITC), Nanonbiotix highlighted new data that suggests NBTXR3 generates immunogenic cell death, which could trigger a specific immune response to attack a tumour. 

This ability to turn tumours ‘hot’ is seen as key to help a person’s immune system fight their cancer.

New data from an ongoing trial of NBTXR3 in Soft Tissue Sarcoma (STS) showed that in patient tumours there was a significant increase of T cells (CD3+, CD8+) and a marked increase of dendritic cell (CD103+) in those who received NBTXR3 plus radiotherapy arm, as opposed to no differences for those treated with radiotherapy alone.

In studies in mice, meanwhile, NBTXR3 with radiotherapy resulted in a control on the untreated tumours (abscopal effect) not seen just with radiation therapy.

Nanobiotix said that taken together, the results confirm that NBTXR3 plus radiotherapy could efficiently prime the adaptive antitumor immune response, turning “cold” tumours in “hot” tumours.

In addition, the response of the body to NBTXR3 with radiotherapy could effectively make an in-situ vaccine, opening up very promising perspectives in the treatment of local cancer and metastases.

PhilW.jpg
Why Invest In Nanobiotix SA? Read More Here

Register here to be notified of future NANO Company articles
View full NANO profile

Nanobiotix SA Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.